Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Salbutamol MDI - GSK

Next Previous
Drug Profile

Salbutamol MDI - GSK

Alternative Names: AH-3365; Albuterol; Albuterol HFA; albuterol hydrofluoroalkane; salbutamol (albuterol) MDI; salbutamol - metered dose; Salbutamol HFA; Salbutamol hydrofluoroalkane; salbutamol pressurised inhalation; Salbutamol sulfate MDI - GlaxoSmithKline; Ventolin

Latest Information Update: 20 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GSK
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Phenols; Small molecules; Tocolytics
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Asthma

Most Recent Events

  • 15 May 2026 Jordan University of Science and Technology plans a phase 0 trial for Pulmonary-atelectasis (Prevention; Treatment-experienced) in Jordan (PO, Inhalant) in June 2026 (NCT07591558)
  • 22 Oct 2025 GSK plans to launch salbutamol MDI for Asthma, in 2026
  • 02 Sep 2025 GlaxoSmithKline completed phase-III clinical trials in Asthma (Treatment-experienced) in USA, Argentina, Australia, Canada, France, Greece, Italy, Panama, Philippines, Poland, Spain, Thailand and United Kingdom (PO) (NCT06261957) (EudraCT2023-509001-76-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top